Though safe, nilotinib does not show promise for benefit for Parkinson’s disease


https://medicalxpress.com/news/2019-12-safe-nilotinib-benefit-parkinson-disease.html


Home
ShareFeedbackAdd to favoritesCommentsNewsletter


 December 5, 2019 , Northwestern University

Northwestern University and the Parkinson Study Group announced that the Nilotinib in Parkinson’s Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for potential repurposing as a Parkinson’s drug, was safe and tolerable in its trial population of 76 participants with moderate to advanced Parkinson’s but does not exert a clinically meaningful benefit or biological effect to benefit those with Parkinson’s disease